Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2023

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

The Business Case for RWE

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Who Moved My Prescription?

Methods that pharma companies can use to make the hub more personalized and experiential.

Transforming the Patient Hub into a Hub of Patient Centricity

Articles

The rise in demand represents the third consecutive month of year-on-year growth. 

October Air Freight Numbers Indicate a Continued Increase in Demand, Says IATA

FDA approves bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, which affects approximately 100,000 people in the United States.

Lyfgenia, Casgevy Become First Cell-Based Gene Therapies to Gain FDA Approval for Sickle Cell Disease

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

A Guide on Determining Stability of Molecular Crystals in Pharmaceutical Drug Development

PrEPVacc tested two different combinations of vaccines to determine whether either can prevent HIV infection in populations at risk of acquiring the virus.

Limited Evidence of Efficacy Halts Study of Novel HIV Vaccine, Oral PrEP

December's installment reinforces the publication's commitment to covering the latest updates on patient support.

Patients are the Priority

Introducing a new style and feel to Pharma Commerce.

Brand Evolution and Engagement

An independent Data Monitoring Committee found that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit vs. Keytruda in combination with chemotherapy followed by Keytruda plus a placebo in patients with metastatic squamous non-small cell lung cancer.

Phase III Trial for Keytruda Combination in Lung Cancer Stopped for Lack of Survival Benefit

Back in Boston, Pharma Commerce tackles all things logistics at LogiPharma USA.

A Supply Chain Overhaul

Will result from Medicare reforms, despite increased drug uptake.

Featured Content

Pharmaceutical Commerce - December 2023

The Business Case for RWE

Who Moved My Prescription?

Transforming the Patient Hub into a Hub of Patient Centricity